A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy
Purpose. To determine the efficacy and safety of preoperative intravitreal conbercept (IVC) injection before vitrectomy for proliferative diabetic retinopathy (PDR). Methods. 107 eyes of 88 patients that underwent pars plana vitrectomy (PPV) for active PDR were enrolled. All patients were assigned r...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2016/2473234 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549870344339456 |
|---|---|
| author | Xiaochun Yang Jianbiao Xu Ruili Wang Yan Mei Huo Lei Jun Liu Ting Zhang Haiyan Zhao |
| author_facet | Xiaochun Yang Jianbiao Xu Ruili Wang Yan Mei Huo Lei Jun Liu Ting Zhang Haiyan Zhao |
| author_sort | Xiaochun Yang |
| collection | DOAJ |
| description | Purpose. To determine the efficacy and safety of preoperative intravitreal conbercept (IVC) injection before vitrectomy for proliferative diabetic retinopathy (PDR). Methods. 107 eyes of 88 patients that underwent pars plana vitrectomy (PPV) for active PDR were enrolled. All patients were assigned randomly to either preoperative IVC group or control group. Follow-up examinations were performed for three months after surgery. The primary bioactivity measures were severity of intraoperative bleeding, incidence of early and late recurrent VH, vitreous clear-up time, and best-corrected visual acuity (BCVA) levels. The secondary safety measures included intraocular pressure, endophthalmitis, rubeosis, tractional retinal detachment, and systemic adverse events. Results. The incidence and severity of intraoperative bleeding were significantly lower in IVC group than in the control group. The average vitreous clear-up time of early recurrent VH was significantly shorter in IVC group compared with that in control group. There was no significant difference in vitreous clear-up time of late recurrent VH between the two groups. Patients that received pretreatment of conbercept had much better BCVA at 3 days, 1 week, and 1 month after surgery than control group. Moreover, both patients with improved BCVA were greater in IVC group than in control group at each follow-up. Conclusions. Conbercept pretreatment could be an effective adjunct to vitrectomy in accelerating postoperative vitreous clear-up and acquiring stable visual acuity restoration for PDR. |
| format | Article |
| id | doaj-art-9b89020e150f4b148c6d668967e97571 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-9b89020e150f4b148c6d668967e975712025-02-03T06:08:26ZengWileyJournal of Ophthalmology2090-004X2090-00582016-01-01201610.1155/2016/24732342473234A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic RetinopathyXiaochun Yang0Jianbiao Xu1Ruili Wang2Yan Mei3Huo Lei4Jun Liu5Ting Zhang6Haiyan Zhao7Department of Ophthalmology, The First People’s Hospital of Yunnan Province, Ocular Fundus Disease Research Center of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Yunnan 650032, ChinaDepartment of General Surgery, The First People’s Hospital of Yunnan Province, Yunnan 650032, ChinaDepartment of Ophthalmology, The First People’s Hospital of Yunnan Province, Ocular Fundus Disease Research Center of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Yunnan 650032, ChinaDepartment of Ophthalmology, The First People’s Hospital of Yunnan Province, Ocular Fundus Disease Research Center of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Yunnan 650032, ChinaDepartment of Ophthalmology, The First People’s Hospital of Yunnan Province, Ocular Fundus Disease Research Center of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Yunnan 650032, ChinaDepartment of Ophthalmology, The First People’s Hospital of Yunnan Province, Ocular Fundus Disease Research Center of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Yunnan 650032, ChinaState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong 510062, ChinaDepartment of Ophthalmology, The First People’s Hospital of Yunnan Province, Ocular Fundus Disease Research Center of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Yunnan 650032, ChinaPurpose. To determine the efficacy and safety of preoperative intravitreal conbercept (IVC) injection before vitrectomy for proliferative diabetic retinopathy (PDR). Methods. 107 eyes of 88 patients that underwent pars plana vitrectomy (PPV) for active PDR were enrolled. All patients were assigned randomly to either preoperative IVC group or control group. Follow-up examinations were performed for three months after surgery. The primary bioactivity measures were severity of intraoperative bleeding, incidence of early and late recurrent VH, vitreous clear-up time, and best-corrected visual acuity (BCVA) levels. The secondary safety measures included intraocular pressure, endophthalmitis, rubeosis, tractional retinal detachment, and systemic adverse events. Results. The incidence and severity of intraoperative bleeding were significantly lower in IVC group than in the control group. The average vitreous clear-up time of early recurrent VH was significantly shorter in IVC group compared with that in control group. There was no significant difference in vitreous clear-up time of late recurrent VH between the two groups. Patients that received pretreatment of conbercept had much better BCVA at 3 days, 1 week, and 1 month after surgery than control group. Moreover, both patients with improved BCVA were greater in IVC group than in control group at each follow-up. Conclusions. Conbercept pretreatment could be an effective adjunct to vitrectomy in accelerating postoperative vitreous clear-up and acquiring stable visual acuity restoration for PDR.http://dx.doi.org/10.1155/2016/2473234 |
| spellingShingle | Xiaochun Yang Jianbiao Xu Ruili Wang Yan Mei Huo Lei Jun Liu Ting Zhang Haiyan Zhao A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy Journal of Ophthalmology |
| title | A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy |
| title_full | A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy |
| title_fullStr | A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy |
| title_full_unstemmed | A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy |
| title_short | A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy |
| title_sort | randomized controlled trial of conbercept pretreatment before vitrectomy in proliferative diabetic retinopathy |
| url | http://dx.doi.org/10.1155/2016/2473234 |
| work_keys_str_mv | AT xiaochunyang arandomizedcontrolledtrialofconberceptpretreatmentbeforevitrectomyinproliferativediabeticretinopathy AT jianbiaoxu arandomizedcontrolledtrialofconberceptpretreatmentbeforevitrectomyinproliferativediabeticretinopathy AT ruiliwang arandomizedcontrolledtrialofconberceptpretreatmentbeforevitrectomyinproliferativediabeticretinopathy AT yanmei arandomizedcontrolledtrialofconberceptpretreatmentbeforevitrectomyinproliferativediabeticretinopathy AT huolei arandomizedcontrolledtrialofconberceptpretreatmentbeforevitrectomyinproliferativediabeticretinopathy AT junliu arandomizedcontrolledtrialofconberceptpretreatmentbeforevitrectomyinproliferativediabeticretinopathy AT tingzhang arandomizedcontrolledtrialofconberceptpretreatmentbeforevitrectomyinproliferativediabeticretinopathy AT haiyanzhao arandomizedcontrolledtrialofconberceptpretreatmentbeforevitrectomyinproliferativediabeticretinopathy AT xiaochunyang randomizedcontrolledtrialofconberceptpretreatmentbeforevitrectomyinproliferativediabeticretinopathy AT jianbiaoxu randomizedcontrolledtrialofconberceptpretreatmentbeforevitrectomyinproliferativediabeticretinopathy AT ruiliwang randomizedcontrolledtrialofconberceptpretreatmentbeforevitrectomyinproliferativediabeticretinopathy AT yanmei randomizedcontrolledtrialofconberceptpretreatmentbeforevitrectomyinproliferativediabeticretinopathy AT huolei randomizedcontrolledtrialofconberceptpretreatmentbeforevitrectomyinproliferativediabeticretinopathy AT junliu randomizedcontrolledtrialofconberceptpretreatmentbeforevitrectomyinproliferativediabeticretinopathy AT tingzhang randomizedcontrolledtrialofconberceptpretreatmentbeforevitrectomyinproliferativediabeticretinopathy AT haiyanzhao randomizedcontrolledtrialofconberceptpretreatmentbeforevitrectomyinproliferativediabeticretinopathy |